Antiphospholipid (aPL)-Positive
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AxiomCA - San Francisco
1 programMENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
AstraZenecaStudy Drug- ALXN1007
AxiomMENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Clinical Trials (2)
Total enrollment: 5,009 patients across 2 trials
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Start: Apr 2014Est. completion: Jun 20169 patients
Phase 2Terminated
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Start: Oct 2026Est. completion: Oct 20295,000 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.